| Cancer type |
Title |
Country |
| Breast cancer |
A phase Ib/II, multicenter, open-label study to evaluate the efficacy of AUY922 in combination with trastuzumab in patients with locally advanced or metasatatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-con |
SE |
| Breast cancer |
A prospective phase II study to evaluate alternations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression efter initial exposure to trastuzumab-taxane based treatment |
SE |
| Colorectal cancer |
Assessmant of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer |
SE |
| Colorectal cancer |
Randomized Double blind Placebo Controlled Gross-over Phase II study on the effects of Lactobacillus Rhamnosus GC supplementation in patients on 1st Line Chemotherapy treatment for Metastatic Coloretctal Cancer- the "lactAXE"- trial |
FI |
| Glioblastoma |
BIBF1120 in patient with glioblastoma and progression after standard therapy /temozolomide and radiotherapy (group 1) or after bevacizumab based secondline therapy (group 2) |
DK |
| Glioblastoma |
Phase I dose escalation of anti-PlGF combined with bevacizumab 10 mg/kg every 2 weeks in recurrent GBM |
DK |
| Lymphoma |
A Two Stage Phase Ib Study to Investigate the Pharmocokinetics and Tolerability of Rituximab Subcutaneous Formulation in Pats With Follicular Lymphoma as Part of Maintenance Treatement |
FI |
| Lymphoma |
Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine,vindesine, temozolomi-de and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomi |
FI |
| Melanoma |
CA184025 Malign melanoma (inop. III and IV) |
NO |
| Multiple diagnosis |
C08-315-01 Transdermally accessible tumour |
NO |
| Multiple diagnosis |
MOC31-PE Advanced mamma, lung, colorectal or prostate carcinoma |
NO |
| Myeloma |
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma |
DK |
| Pancreatic cancer |
Bay86-9766 And Gemcitabine in PAncreatic Cancer (BAGPAC) |
NO |
| Pancreatic cancer |
Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer |
SE |
| Solide tumores |
A phase 1, open label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function |
SE |
| Solide tumores |
CMEK162X2102 All solid tumors with BRAF or RAF mutation |
NO |
| Solide tumores |
First study of intravenous catumaxumab (Removab) in patients with EpCam expressing epithelial solid tumors |
DK |
| Solide tumores |
Second generation Braf inhibitor (after lead compound vemurafenib) in Braf mutated solid tumors, and extension phase in melanomas and colorectal cancer |
DK |
| Solide tumores |
TWEAK-antibody in patients with Fn14 expressing solid tumors, first in humans study |
DK |
